Les programmes de prise en charge des maladies chroniques et de la multimorbidité en Suisse

Le nombre et la couverture des programmes de prise en charge des maladies chroniques est insuffisant en Suisse. Dans le cadre de la préparation du rapport national suisse sur la santé 2015, l'Observatoire suisse de la santé a fait réaliser un état des lieux des programmes de prise en charge des maladies chroniques et de la multimorbidité en Suisse. Une enquête téléphonique selon la méthode boule de neige a permis d'identifier 44 programmes actifs dans quatorze cantons; ces programmes sont décrits plus précisément dans l'étude. Il s'agit d'une augmentation marquée, si on compare ces résultats avec ceux d'une enquête similaire réalisée en 2007 et qui avait dénombré sept programmes. Le nombre et la couverture de ces programmes sont, selon les auteurs, largement insuffisants pour permettre un impact réel et mesurable sur la santé et la prise en charge de tous les patients chroniques résidant en Suisse.

Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.

OBJECTIVE: The goal was to demonstrate that tailored therapy, according to tumor histology and epidermal growth factor receptor (EGFR) mutation status, and the introduction of novel drug combinations in the treatment of advanced non-small-cell lung cancer are promising for further investigation. METHODS: We conducted a multicenter phase II trial with mandatory EGFR testing and 2 strata. Patients with EGFR wild type received 4 cycles of bevacizumab, pemetrexed, and cisplatin, followed by maintenance with bevacizumab and pemetrexed until progression. Patients with EGFR mutations received bevacizumab and erlotinib until progression. Patients had computed tomography scans every 6 weeks and repeat biopsy at progression. The primary end point was progression-free survival (PFS) ≥ 35% at 6 months in stratum EGFR wild type; 77 patients were required to reach a power of 90% with an alpha of 5%. Secondary end points were median PFS, overall survival, best overall response rate (ORR), and tolerability. Further biomarkers and biopsy at progression were also evaluated. RESULTS: A total of 77 evaluable patients with EGFR wild type received an average of 9 cycles (range, 1-25). PFS at 6 months was 45.5%, median PFS was 6.9 months, overall survival was 12.1 months, and ORR was 62%. Kirsten rat sarcoma oncogene mutations and circulating vascular endothelial growth factor negatively correlated with survival, but thymidylate synthase expression did not. A total of 20 patients with EGFR mutations received an average of 16 cycles. PFS at 6 months was 70%, median PFS was 14 months, and ORR was 70%. Biopsy at progression was safe and successful in 71% of the cases. CONCLUSIONS: Both combination therapies were promising for further studies. Biopsy at progression was feasible and will be part of future SAKK studies to investigate molecular mechanisms of resistance.